118 related articles for article (PubMed ID: 38710993)
1. Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Bateman NW; Abulez T; Soltis AR; McPherson A; Choi S; Garsed DW; Pandey A; Tian C; Hood BL; Conrads KA; Teng PN; Oliver J; Gist G; Mitchell D; Litzi TJ; Tarney CM; Crothers BA; Mhawech-Fauceglia P; Dalgard CL; Wilkerson MD; Pierobon M; Petricoin EF; Yan C; Meerzaman D; Bodelon C; Wentzensen N; Lee JSH; ; Huntsman DG; Shah S; Shriver CD; Phippen NT; Darcy KM; Bowtell DDL; Conrads TP; Maxwell GL
NPJ Precis Oncol; 2024 May; 8(1):97. PubMed ID: 38710993
[No Abstract] [Full Text] [Related]
2. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Bateman NW; Abulez T; Soltis AR; McPherson A; Choi S; Garsed DW; Pandey A; Tian C; Hood BL; Conrads KA; Teng PN; Oliver J; Gist G; Mitchell D; Litzi TJ; Tarney CM; Crothers BA; Mhawech-Fauceglia P; Dalgard CL; Wilkerson MD; Pierobon M; Petricoin EF; Yan C; Meerzaman D; Bodelon C; Wentzensen N; Lee JSH; ; Huntsman DG; Shah S; Shriver CD; Phippen NT; Darcy KM; Bowtell DDL; Conrads TP; Maxwell GL
NPJ Precis Oncol; 2024 Mar; 8(1):68. PubMed ID: 38480868
[TBL] [Abstract][Full Text] [Related]
3. Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
Lupia M; Melocchi V; Bizzaro F; Lo Riso P; Dama E; Baronio M; Ranghiero A; Barberis M; Bernard L; Bertalot G; Giavazzi R; Testa G; Bianchi F; Cavallaro U
Int J Cancer; 2022 Jul; 151(2):240-254. PubMed ID: 35218560
[TBL] [Abstract][Full Text] [Related]
4. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
5. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S; Kennedy JJ; Ivey RG; Murillo OD; Hosseini N; Song X; Petralia F; Calinawan A; Savage SR; Berry AB; Reva B; Ozbek U; Krek A; Ma W; da Veiga Leprevost F; Ji J; Yoo S; Lin C; Voytovich UJ; Huang Y; Lee SH; Bergan L; Lorentzen TD; Mesri M; Rodriguez H; Hoofnagle AN; Herbert ZT; Nesvizhskii AI; Zhang B; Whiteaker JR; Fenyo D; McKerrow W; Wang J; Schürer SC; Stathias V; Chen XS; Barcellos-Hoff MH; Starr TK; Winterhoff BJ; Nelson AC; Mok SC; Kaufmann SH; Drescher C; Cieslik M; Wang P; Birrer MJ; Paulovich AG
Cell; 2023 Aug; 186(16):3476-3498.e35. PubMed ID: 37541199
[TBL] [Abstract][Full Text] [Related]
7. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes.
Hyeon DY; Nam D; Han Y; Kim DK; Kim G; Kim D; Bae J; Back S; Mun DG; Madar IH; Lee H; Kim SJ; Kim H; Hyun S; Kim CR; Choi SA; Kim YR; Jeong J; Jeon S; Choo YW; Lee KB; Kwon W; Choi S; Goo T; Park T; Suh YA; Kim H; Ku JL; Kim MS; Paek E; Park D; Jung K; Baek SH; Jang JY; Hwang D; Lee SW
Nat Cancer; 2023 May; 4(5):774. PubMed ID: 37208505
[No Abstract] [Full Text] [Related]
10. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.
Soltis AR; Bateman NW; Liu J; Nguyen T; Franks TJ; Zhang X; Dalgard CL; Viollet C; Somiari S; Yan C; Zeman K; Skinner WJ; Lee JSH; Pollard HB; Turner C; Petricoin EF; Meerzaman D; Conrads TP; Hu H; ; Shriver CD; Moskaluk CA; Browning RF; Wilkerson MD
Cell Rep Med; 2022 Nov; 3(11):100819. PubMed ID: 36384096
[TBL] [Abstract][Full Text] [Related]
11. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract][Full Text] [Related]
13. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
15. A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.
Zhao Y; Yang SM; Jin YL; Xiong GW; Wang P; Snijders AM; Mao JH; Zhang XW; Hang B
J Oncol; 2019; 2019():3614207. PubMed ID: 31885574
[TBL] [Abstract][Full Text] [Related]
16. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
Luo X; Cao J; Zhang C; Huang H; Liu J
Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes.
Meng C; Sun Y; Liu G
Front Oncol; 2023; 13():1144430. PubMed ID: 37256178
[TBL] [Abstract][Full Text] [Related]
18. High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.
D'Hondt V; Lacroix-Triki M; Jarlier M; Boissiere-Michot F; Puech C; Coopman P; Katsaros D; Freiss G
Oncotarget; 2017 Nov; 8(56):95662-95673. PubMed ID: 29221157
[TBL] [Abstract][Full Text] [Related]
19. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
20. Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.
Si M; Zhang J; Cao J; Xie Z; Shu S; Zhu Y; Lang J
Onco Targets Ther; 2019; 12():10057-10075. PubMed ID: 31819501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
